• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Mechanism of cancer progression mediated by IL-32-Gankyrin axis in intrahepatic cholangiocarcinoma

Research Project

  • PDF
Project/Area Number 19K09190
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55020:Digestive surgery-related
Research InstitutionChiba University

Principal Investigator

Mishima Takashi  千葉大学, 医学部附属病院, 助教 (70802560)

Co-Investigator(Kenkyū-buntansha) 野島 広之  帝京大学, 医学部, 講師 (10507320)
高野 重紹  千葉大学, 医学部附属病院, 講師 (20436380)
久保木 知  千葉大学, 大学院医学研究院, 講師 (50571410)
大塚 将之  千葉大学, 大学院医学研究院, 教授 (90334185)
Project Period (FY) 2019-04-01 – 2022-03-31
Keywords肝内胆管癌 / IL-32 / Gankyrin
Outline of Final Research Achievements

Results of the immunohistochemical staining of 75 resected intrahepatic cholangiocarcinoma cases in our department revealed that the group with high gankyrin expression in tumor cells had a significantly worse prognosis. However, the prognosis of the group with high interleukin-32 (IL-32) expression in tumor cells was not different from the group with low IL-32 expression.
However, in the evaluation of IL-32 expression in peritumoral tissues, the group with high IL-32 expression in peritumoral tissues (tumor stroma) had a significantly worse prognosis compared to the group with low IL-32 expression (p = 0.05). Furthermore, many of the patients with high IL-32 expression in the peritumoral tissues had vascular invasion, suggesting that IL-32 may influence the maintenance of tumor cells’ malignancy potential in a paracrine manner.

Free Research Field

消化器外科学

Academic Significance and Societal Importance of the Research Achievements

IL-32とGankyrinの関連は明らかには出来ていないものの、IL-32は肝内胆管癌において、腫瘍周囲から悪性度の維持などの影響を及ぼしている可能性がある。IL-32は癌腫によりその働きは違い、悪性度を高めているものから弱めるものまで様々である。しかし、肝内胆管癌においては悪性度を高める方向に働いている事が本研究により示唆された。今後も細胞レベルでの研究を続けることで、新たな治療ターゲットの一つとなる可能性が示された。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi